Modeling the impact of a long-term horizon and multiple treatment episodes on estimates of the cost-effectiveness of alcohol treatment in the United States

被引:2
|
作者
Barbosa, Carolina [1 ]
Dowd, William N. [1 ]
Karriker-Jaffe, Katherine J. [2 ,3 ]
Zarkin, Gary [1 ]
机构
[1] RTI Int, 3040 East Cornwallis Rd,POB 12194, Res Triangle Pk, NC 27709 USA
[2] RTI Int, Berkeley, CA USA
[3] RTI Int, Behav Hlth Res Div, 2150 Shattuck Ave,Suite 800, Berkeley, CA 94704 USA
关键词
alcohol treatment; alcohol use disorder; cost-effectiveness analysis; drinking patterns; simulation modeling; USE DISORDERS; RISK DRINKING; CONSUMPTION; DEPENDENCE; HEALTH; COMBINE; PHARMACOTHERAPY; INTERVENTIONS; MORTALITY; OUTCOMES;
D O I
10.1111/acer.15186
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
BackgroundMost clinical studies of alcohol use disorder (AUD) treatment have short follow-up periods, underestimating the full benefits of alcohol treatment. Furthermore, clinical studies only consider one treatment cycle and do not account for the need for multiple episodes to treat a chronic recurrent condition.MethodsA validated microsimulation model of the long-term drinking patterns of people with AUD in the United States simulated 10,000 individuals resembling those from a large clinical trial. The model was used to assess the impact of (1) 1-year, 5-year, and lifetime horizon on alcohol treatment cost-effectiveness estimates and (2) no, one, two, four, and unlimited additional treatment episodes on alcohol treatment cost-effectiveness estimates. Model outcomes included healthcare costs, crime costs, labor market productivity, life expectancy, quality-adjusted life years (QALYs), alcohol-related hospitalizations, and deaths. Cost-effectiveness analyses were conducted for two perspectives: a healthcare perspective that included costs from hospitalization and AUD treatment, and a broader societal perspective that also included crime costs and productivity.ResultsThe incremental cost per additional QALY gained for alcohol treatment compared with no treatment decreased from $55,590 after 1 year to $78 when healthcare costs and QALYs were tracked over the lifetime, that is, treatment became more cost effective. Treatment was cost saving for any time frame when the impacts on crime and labor productivity were also accounted for in a societal perspective. Access to multiple treatment episodes dominated (i.e., it was more effective and less costly) than no-treatment and one-episode scenarios. From a healthcare perspective, incremental costs per additional QALY for increasing from a maximum of two to four treatment episodes was $499 and from four to unlimited episodes was $5049. The unlimited treatment scenario dominated all others from a societal perspective. Results were robust in sensitivity analyses.ConclusionsA long-term perspective and multiple episodes of alcohol treatment improve cost-effectiveness estimates. When societal impacts are included, alcohol treatment is cost saving. Results support the value of alcohol treatment.
引用
收藏
页码:2121 / 2137
页数:17
相关论文
共 50 条
  • [31] THE COST-EFFECTIVENESS OF PREGABALIN (LYRICA®) IN THE TREATMENT OF SEVERE FIBROMYALGIA IN THE UNITED STATES
    Lloyd, A.
    Castelnuovo, E.
    Boomershine, C. S.
    Choy, E.
    Chandran, A.
    Zlateva, G.
    VALUE IN HEALTH, 2010, 13 (03) : A126 - A126
  • [32] EVALUATING THE COST-EFFECTIVENESS OF VOCLOSPORIN IN THE UNITED STATES FOR THE TREATMENT OF LUPUS NEPHRITIS
    Flauto, Ronald
    Lee, Ernie
    Atencio, Victoria
    Birardi, Vanessa
    Kennedy, Lisa
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2024, 83 (04) : S113 - S113
  • [33] Modelling the cost-effectiveness of tofacitinib for the treatment of rheumatoid arthritis in the United States
    Claxton, Lindsay
    Taylor, Matthew
    Gerber, Robert A.
    Gruben, David
    Moynagh, Dermot
    Singh, Amitabh
    Wallenstein, Gene, V
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (11) : 1991 - 2000
  • [34] Evaluating the cost-effectiveness of voclosporin for the treatment of lupus nephritis in the United States
    Kennedy, Lisa
    Lee, Ernie
    Flauto, Ronald
    Atencio, Victoria
    Birardi, Vanessa
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2024, 30 (08): : 773 - 781
  • [35] Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly
    Lin, Liang
    Teng, Monica
    Zhao, Ying Jiao
    Khoo, Ai Leng
    Seet, Raymond Chee Seong
    Yong, Quek Wei
    Yeo, Tiong Cheng
    Lim, Boon Peng
    CARDIOVASCULAR DRUGS AND THERAPY, 2015, 29 (02) : 187 - 197
  • [36] A Review of Methods Used in Long-Term Cost-Effectiveness Models of Diabetes Mellitus Treatment
    Tarride, Jean-Eric
    Hopkins, Robert
    Blackhouse, Gord
    Bowen, James M.
    Bischof, Matthias
    Von Keyserlingk, Camilla
    O'Reilly, Daria
    Xie, Feng
    Goeree, Ron
    PHARMACOECONOMICS, 2010, 28 (04) : 255 - 277
  • [37] Long-term cost-effectiveness analysis of sacral neuromodulation in the treatment of severe faecal incontinence
    Valencia, Mario de Miguel J.
    Hita, Juan Cabases M.
    Iriso, Eduardo Sanchez
    Martinez, Fabiola Oteiza
    Ibanez, Inaki Alberdi
    Lopez, Alfonso Alvarez
    Hurtado, Hector Ortiz
    Velasco, Mario J. de Miguel J.
    COLORECTAL DISEASE, 2023, 25 (09) : 1821 - 1831
  • [38] A Review of Methods Used in Long-Term Cost-Effectiveness Models of Diabetes Mellitus Treatment
    Jean-Eric Tarride
    Robert Hopkins
    Gord Blackhouse
    James M. Bowen
    Matthias Bischof
    Camilla Von Keyserlingk
    Daria O’Reilly
    Feng Xie
    Ron Goeree
    PharmacoEconomics, 2010, 28 : 255 - 277
  • [39] Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly
    Liang Lin
    Monica Teng
    Ying Jiao Zhao
    Ai Leng Khoo
    Raymond Chee Seong Seet
    Quek Wei Yong
    Tiong Cheng Yeo
    Boon Peng Lim
    Cardiovascular Drugs and Therapy, 2015, 29 : 187 - 197
  • [40] A COST-EFFECTIVENESS ANALYSIS OF ALTERNATIVE APPROACHES FOR LONG-TERM TREATMENT OF PROXIMAL VENOUS THROMBOSIS
    HULL, R
    RASKOB, G
    HIRSH, J
    THROMBOSIS AND HAEMOSTASIS, 1983, 50 (01) : 66 - 66